SL: Writing review and editing
4 In TRANSCEND-T2D-1, Lillys first Phase 3 trial in adults with type 2 diabetes (537 participants, 40 weeks), retatrutide produced 16.8% weight loss at the 12 mg dose
When semaglutide binds to these receptors, it signals the brain to reduce hunger and increase satiety, leading to reduced calorie intake and weight loss
Presented for research literature review only Koskelo K et al
Tuy nhin, hy thn trng v vic kt hp tht v ni tng thc t vo ch n ung ca mnh, hy chn la ni cung cp tin cy, m bo t tiu chun chn nui v hm lng cht ph gia c thm vo trong qu trnh bo qun mc cho php
However, patients must understand the difference between trial results and approved treatment